albany, NY -- (SBWIRE) -- 02/04/2019 -- Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology and Market Forecast-2027

04 Feb. 19

The total prevalent population of ATTR in the 7 major markets is approximately 19,344 cases in 2017.

Request for sample pages

1. Transthyretin is an abundant, soluble, ?-strand rich 55 kDa homotetramer serum protein that is responsible for the transportation of both vitamin A and thyroxin throughout the body.
2. DelveInsight also estimates higher prevalence of ATTR in the Italy with approximately 2,069 cases in 2017 followed by France. On the other hand, United Kingdom had the lowest prevalent population in 2017
3. DelveInsight estimates that the diagnosed prevalent population of ATTR will significantly increase.

(Albany, US) DelveInsight launched a new report on Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology and Market Forecast-2027

Key topics covered

1. This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Transthyretin Amyloidosis market
2. Organize sales and marketing efforts by identifying the best opportunities for Transthyretin Amyloidosis market
3. To understand the future market competition in the Transthyretin Amyloidosis market

"Hereditary transthyretin amyloidosis (hATTR) cases are segmented in to two segments which includes Familial Amyloid Polyneuropathy (FAP) and Familial Amyloid Cardiomyopathy (FAC) cases. In 2017, there were approximately 5,241 cases of Familial Amyloid Polyneuropathy and XXX cases of Familial Amyloid Cardiomyopathy in the 7MM"

The therapeutic market of Transthyretin Amyloidosis (ATTR) in the seven major markets is approximately USD 336.0 million in 2017. The United States accounts for the largest market size of ATTR, in comparison with EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan. United States accounts for approximately 54.5% of the total sales in 2017.

ATTR market has been assessed, based on demand, prescription analysis and annual cost of therapy of supportive therapies; current and forecasted market value of the approved drug as well as forecasted patient share and annual cost of therapy of upcoming drugs. Supportive therapies like Diflunisal, other symptomatic drugs for TTR-FAP and recommended symptomatic drugs like loop diuretics, aldosterone antagonists, angiotensin-converting enzyme inhibitors, and beta blockers have been considered for TTR-CM market estimation.

The dynamics of ATTR market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period of 2019-2028.

Companies covered

1. Corino Therapeutics
2. Eidos Therapeutics
3. Prothena Biosciences
4. Pfizer Inc.
5. Alnylam Pharmaceuticals
And many others

Drugs covered

1. CRX-1008
2. Vyndaqel
3. Onpattro
4. Tegsedi
And many others

Table of contents
1. Key Insights
2. Transthyretin Amyloidosis Market Overview at a Glance
3. Disease Background and Overview: Transthyretin-related amyloidosis (ATTR)
3.1. Introduction
3.2. Clinical aspects of ATTR
3.3. Types of Transthyretin Amyloidosis (ATTR)
3.4. Disease Causes
3.5. ATTR-Symptoms
3.6. Pathogenesis
3.7. ATTR Diagnosis
3.7.1. Diseases with symptoms that overlap with that of hATTP amyloidosis
3.7.2. Red flag symptoms associated with hATTR Amyloidosis
3.7.3. Confirmation of hATTR Amyloidosis diagnosis
3.7.4. Tools for evaluating TTR-FAP progression
3.7.5. Tests for detecting Carpal tunnel syndrome
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)
4.4. 7MM Diagnosed Prevalent Population of Transthyretin Amyloidosis (ATTR)-Type Specific
5. Country Wise-Epidemiology of Transthyretin Amyloidosis (ATTR)
5.1. United States
5.1.1. Diagnosed Prevalent Population of ATTR in the United States
5.1.2. Type-specific Diagnosed Prevalent Population of hATTR in the United States
5.1.3. Treatable cases of Transthyretin Amyloidosis in the United States
5.2. Germany
5.2.1. Diagnosed Prevalent Population of ATTR in Germany
5.2.2. Type-specific Diagnosed Prevalent Population of hATTR in Germany
5.2.3. Treatable cases of Transthyretin Amyloidosis in Germany
5.3. France
5.3.1. Diagnosed Prevalent Population of ATTR in France
5.3.2. Type-specific Diagnosed Prevalent Population of hATTR in France
5.3.3. Treatable cases of Transthyretin Amyloidosis in France
5.4. Italy
5.4.1. Diagnosed Prevalent Population of ATTR in Italy
5.4.2. Type-specific Diagnosed Prevalent Population of hATTR in Italy
5.4.3. Treatable cases of Transthyretin Amyloidosis in Italy
5.5. Spain
5.5.1. Diagnosed Prevalent Population of ATTR in Spain
5.5.2. Type-specific Diagnosed Prevalent Population of hATTR in Spain
5.5.3. Treatable cases of Transthyretin Amyloidosis in Spain
5.6. United Kingdom
5.6.1. Diagnosed Prevalent Population of ATTR in the United Kingdom
5.6.2. Type-specific Diagnosed Prevalent Population of hATTR in the United Kingdom
5.6.3. Treatable cases of Transthyretin Amyloidosis in the United Kingdom
5.7. Japan
5.7.1. Diagnosed Prevalent Population of ATTR in Japan
5.7.2. Type-specific Diagnosed Prevalent Population of hATTR in Japan
5.7.3. Treatable cases of Transthyretin Amyloidosis in Japan
6. Diagnosed Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.1. United States: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.2. Germany: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.3. France: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.4. Italy: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.5. Spain: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.6. United Kingdom: Surgery Cases of ATTR related Carpal Tunnel Syndrome
6.7. Japan: Surgery Cases of ATTR related Carpal Tunnel Syndrome
7. Current Treatment and Medical Practices
7.1. Treatment Algorithm
7.2. Supportive non-disease modifying therapies for ATTR-cardiac amyloidosis:
7.3. Treatment Guidelines
7.3.1. First European Consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
7.4. TTP stages according to symptom severity
7.5. Algorithm for treatment of TTR-FAP
8. Unmet Needs
9. Marketed Drugs
9.1. Vyndaqel: Pfizer Inc.
9.1.1. Drug Description
9.1.2. Mechanism of Action
9.1.3. Regulatory Milestones
9.1.4. Advantages & Disadvantages
9.1.5. Safety and Efficacy
9.1.6. Ongoing trial description, 2017
9.1.7. Product Profile
10. Emerging Therapies
11. Key Cross Competition
12. Phase III and Filed Drugs
12.1. Patisiran: Alnylam Pharmaceuticals
12.2. Inotersen: Ionis Pharmaceuticals Inc.
13. Phase II Drugs
13.1. CRX-1008: Corino Therapeutics Inc.
14. Transthyretin Amyloidosis: Market Analysis
15. Key Findings
15.1. Transthyretin Amyloidosis: 7 Major Market Analysis
15.2. Therapy Based Market size of Transthyretin Amyloidosis in 7MM
15.3. Therapy Based Market size of Transthyretin Amyloidosis by ATTR Types in 7MM
15.4. Familial Amyloid Polyneuropathy (FAP)
15.5. Familial Amyloid Cardiomyopathy (FAC)
15.6. Non-Hereditary TTR/ WT-TTR
16. Market Size of Transthyretin Amyloidosis (ATTR) broken down by Country
16.1. United States Market Analysis
16.1.1. Type Specific Market size of Transthyretin Amyloidosis in the United States
16.1.2. Therapy Based Market size Transthyretin Amyloidosis in the United States
16.1.3. Therapy Based Market size Transthyretin Amyloidosis by ATTR Types in the United States
16.2. EU5: Market Analysis
16.3. Germany Market Analysis
16.4. France Market Analysis
16.5. Spain Market Analysis
16.6. Italy Market Analysis
16.7. United Kingdom
16.8. Japan
17. Market Drivers
18. Market Barriers
19. Appendix
19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330